Residual volume/total lung capacity ratio confers limited additive significance to lung clearance index for assessment of adults with bronchiectasis

Wei-jie Guan¹,²*, Jing-jing Yuan¹, Yan Huang¹, Hui-min Li¹, Rong-chang Chen¹*, Nanshan Zhong¹

¹ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China, ² Sino-French Hoffmann Institute, Guangzhou Medical University, Guangzhou, China

* chenc@vip.163.com (RCC); battery203@163.com (WJG)

Abstract

Background
Mosaicism and hyperinflation are common pathophysiologic features of bronchiectasis. The magnitude of ventilation heterogeneity might have been affected by the degree of hyperinflation. Some studies have evaluated the discriminative performance of lung clearance index (LCI) in bronchiectasis patients, but the additive diagnostic value of hyperinflation metrics to LCI is unknown.

Objective
To compare LCI and the ratio of residual volume to total lung capacity (RV/TLC), along with the LCI normalized with RV/TLC, in terms of discriminative performance, correlation and concordance with clinical variables in adults with bronchiectasis.

Methods
Measurement items included chest high-resolution computed tomography, multiple-breath nitrogen washout test, spirometry, and sputum culture. We analyzed bronchodilator responses by stratifying LCI and RV/TLC according to their median levels (LCI High/RV/TLC High, LCI Low/RV/TLC High, LCI High/RV/TLC Low, and LCI Low/RV/TLC Low).

Results
Data from 127 adults with clinically stable bronchiectasis were analyzed. LCI had greater diagnostic value than RV/TLC in discriminating moderate-to-severe from mild bronchiectasis, had greater concordance in reflecting clinical characteristics (including the number of bronchiectatic lobes, radiological severity score, and the presence of cystic bronchiectasis). Normalization of LCI with RV/TLC did not contribute to greater discriminative performance.
or concordance with clinical variables. The LCI, before and after normalization with RV/TLC, correlated statistically with age, sex, HRCT score, *Pseudomonas aeruginosa* colonization, cystic bronchiectasis, and ventilation heterogeneity (all $P<0.05$). Different bronchodilator responses were not significant among the four subgroups of bronchiectasis patients, including those with discordant LCI and RV/TLC levels.

**Conclusion**

LCI is superior to RV/TLC for bronchiectasis assessment. Normalization with RV/TLC is not required. Stratification of LCI and RV/TLC is not associated with significantly different bronchodilator responses.

**Introduction**

Ventilation heterogeneity, which exists in physiologic conditions [1], aggravates in chronic airway diseases including cystic fibrosis (CF) [2] and bronchiectasis [3–6]. The underlying causes for worsening ventilation heterogeneity are multifaceted, including mucus plugging [5] and airway remodeling [7] which are cascades of lung infections [8,9]. Such events can be readily observed in bronchiectasis regardless of the etiology (e.g. post-tuberculous infection) [3]. Lung clearance index (LCI) has been shown to sensitively detect ventilation heterogeneity and correlate with disease severity metrics, such as high-resolution computed tomography (HRCT) scores, in bronchiectasis [3–6]. Compared with spirometry, LCI conferred greater sensitivity in identifying early-stage lung structural disorders, which are likely related to small airways [3]. LCI has also been shown to be a sensitive, repeatable and practical parameter for assessing airway disorders in adults with cystic fibrosis [10].

Hyperinflation correlates with airway remodeling and disease severity in COPD [11,12]. In patients with bronchiectasis, airway destruction and remodeling may have predisposed to lung hyperinflation, which could be partially reflected by the functional residual capacity, measured with multiple-breath gas washout tests (MBW) [13]. The ratio of residual volume to total lung capacity (RV/TLC) is a more comprehensive parameter that could be readily calculated based on the functional residual capacity. Compared with HRCT-related hyperinflation metrics, RV/TLC can be inferred from the functional residual capacity measured with MBW, which measures the LCI with no potential risk of radiation exposures. It is hypothesized that more severe hyperinflation might contribute to greater magnitude of ventilation heterogeneity because of greater dead space volume which hinders regional ventilation and/or gas exchange. Currently, it remains unclear whether inhaled bronchodilators (such as salbutamol) result in a different magnitude of improvement in hyperinflation and ventilation heterogeneity. How the two metrics correlate with, and differ from, each other in bronchiectasis has not been documented.

Our research hypothesis was that LCI correlated with the RV/TLC, that LCI might be affected the RV/TLC, and that adjustment with RV/TLC could potentially improve the discriminative performance of LCI in patients with bronchiectasis. Therefore, we investigated the discriminative performance of RV/TLC and LCI, and the concordance and correlation with clinical parameters. We normalized LCI with RV/TLC to determine whether this would improve the discriminative performance of LCI. Finally, we assessed bronchodilator responses by stratifying the RV/TLC and LCI according to their median values (LCI$_{\text{High}}$/RV/TLC$_{\text{High}}$, LCI$_{\text{Low}}$/RV/TLC$_{\text{High}}$, LCI$_{\text{High}}$/RV/TLC$_{\text{Low}}$, and LCI$_{\text{Low}}$/RV/TLC$_{\text{Low}}$). These might help
address the question whether RV/TLC should be taken into account when LCI was adopted
for assessment of ventilatory heterogeneity in patients with bronchiectasis.

Methods

Patients

Enrollment of consecutive bronchiectasis patients was conducted between March 2014 and
May 2016. Diagnosis of bronchiectasis was made according to chest HRCT, effective within 12
months. Patients were aged 18 years or greater, and had no exacerbation for more than 4
weeks. Exacerbation should meet three or more criteria (persisting for >24hrs): significantly
increased cough frequency; increased sputum purulence/volume; dyspnea; fever; hemoptysis;
exercise intolerance; chest pain; increased pulmonary infiltration [6,14]. Exclusion criteria
were antibiotics use within 4 weeks, malignancy, and failure to undergo measurements. To
analyze discriminative performance in real-world settings, concomitant respiratory diseases
(e.g. asthma) were not excluded.

Study protocol approval was obtained from Ethics Committee of The First Affiliated Hospi-
tal of Guangzhou Medical University. All patients gave written informed consent.

Study design

The discriminative performance of LCI and RV/TLC%, and their association with clinical
parameters of bronchiectasis were evaluated. Assessment included history inquiry, multiple-
breath washout test, spirometry, and sputum culture. All baseline measurements were per-
formed within 12 months of the chest HRCT assessment. To determine how ventilation het-
erogeneity or air trapping correlated with bronchodilator responses, we stratified according to
LCI and RV/TLC (see details below). Our study design complied with the STROBE guideline
(S1 Text).

Clinical assessments

A radiologist with working experience of more than 10 years evaluated the CT scans and
graded the radiological severity. Chest HRCT score was evaluated using modified Reiff score
(0–6 points, mild bronchiectasis; 7–12 points, moderate bronchiectasis; 13–18 points, severe
bronchiectasis) [6,14]. Dyshomogeneity (mosaicism), cystic bronchiectasis (denoted the pres-
ence of cystic changes of the dilated bronchi on chest HRCT), and the number of bronchiecta-
tic lobes were evaluated.

A full description of the MBW is available in the Online Supplement text (S2 Text). MBW
[6,15] with nitrogen as tracer gas was performed before spirometry, to derive the LCI values.
Reference values of spirometry were derived from validated equations [16]. Following all
MBW maneuvers which measured the functional residual volume, patients underwent slow
vital capacity measurement in which an inspiratory and expiratory maneuver was involved,
which was applied to calculate the total lung capacity and RV/TLC. The maximal values of
forced vital capacity (FVC) and forced expiratory volume in one second (FEV₁) were reported
for spirometry. Bronchial dilation test was performed within the same day of LCI and RV/TLC
measurement, in a subgroup of patients (concurrent bronchodilation test cohort) with FEV₁
<80% predicted to minimize ceiling bronchodilator effects [14]. Inhaled long-acting beta-ago-
nists or muscarinic receptor antagonists should be withheld for at least 12 hours, whereas
short-acting beta-agonists or muscarinic receptor antagonists were withheld for at least 8
hours before bronchodilation test. Given small sample sizes, we also compared bronchodilator
responses in patients who had ever undergone bronchodilation test within 2 years. Data were
pooled (concurrent & previous bronchodilation test cohort) to increase statistical power of identifying different bronchodilator responses.

Following removal of oral debris, fresh sputum was obtained within 2 hours of sampling at initial visits. Bacterial (e.g. *Pseudomonas aeruginosa*) colonization was defined as two or more occasions (more than three months apart) with identical pathogenic bacteria being isolated from sputum within the nearest one year [16,17]. *Bronchiectasis Severity Index* (BSI) was employed to measure bronchiectasis severity, with 0–4, 5–8, and 9 points or greater corresponding to mild, moderate and severe bronchiectasis, respectively [17].

**Statistical analysis**

Mean ± standard deviation or median (interquartile range) was expressed for numerical data, and compared with independent t-test or Mann-Whitney test. No. (%) was used for describing dichotomous data, and compared using chi-square tests.

LCI was normalized with RV/TLC (nLCI, calculated as dividing the LCI by RV/TLC) to assess whether it would improve discriminative performance of LCI. We adopted receiver operating characteristic (ROC) curve to compare how RV/TLC, LCI and nLCI discriminated moderate-to-severe from mild bronchiectasis, and mild-to-moderate from severe bronchiectasis according to BSI score. The area under curve (AUC), 95% confidence intervals (95%CI), sensitivity, specificity, accuracy and cut-off were calculated. The AUC was compared with MedCalc (MedCalc Inc., Ostend, Belgium). Chi-square test was applied to determine the consistency for dichotomous results of RV/TLC and LCI (lower and upper 50th percentile). We assessed the correlation between RV/TLC and LCI, using partial correlation model with adjustment for age, sex, body-mass index and baseline FEV1,% predicted.

We determined clinical variable attributes’ impacts on LCI, RV/TLC and nLCI using generalized linear mixed model, with factors of sex, sputum bacteriology (*Pseudomonas aeruginosa*/non-*Pseudomonas aeruginosa* colonized), cystic bronchiectasis (yes/no) and mosaicism (yes/no) as factors, and covariates of the number of bronchiectatic lobes, HRCT total score, age and baseline FEV1,% predicted for fitting fixed-effect estimates.

To determine whether bronchodilator responses differ with ventilation heterogeneity and hyperinflation, RV/TLC (high vs. low) and LCI (high vs. low) were dichotomized according to their medians among all patients. Clinical characteristics of patients with higher RV/TLC and higher LCI (RV/TLCHigh/LCIHigh), lower RV/TLC and higher LCI (RV/TLCLow/LCILow), higher RV/TLC and lower LCI (RV/TLCHigh/LCILow), and lower RV/TLC and lower LCI (RV/TLCLow/LCILow) were compared. We did not adjust for multiple comparisons, therefore between-group comparisons were descriptive in nature.

Finally, we evaluated the correlation between bronchodilator responses (expressed either as improvement in FEV1 absolute values or percentage) and RV/TLC% and LCI.

Data analyses were processed with SPSS 16.0 package (SPSS Inc., Chicago, USA) and Graphpad Prism 5.0 (Graphpad Inc., San Diego, USA) unless otherwise stated. *P*<0.05 was deemed statistically significant.

**Results**

**Subject enrollment**

Data from 127 out of 166 patients who underwent screening were analyzed. 42 and 47 patients underwent bronchodilation test at baseline and at least once within 2 years, respectively (Fig 1). Bronchodilator response was evaluated in concurrent bronchodilation test cohort (n = 42) and pooled cohort (concurrent & previous bronchodilation test cohort, n = 88), respectively.
Clinical characteristics

Of 127 bronchiectasis patients, most were female and never-smokers. The median BSI was 6.0. *Pseudomonas aeruginosa* was isolated from ~33% of cases. 85.8% of patients were never-smokers. 70% of patients had administered mucolytics within 6 months, but none was using inhaled antibiotics. Idiopathic and post-infectious constituted the most common etiologies. Asthma was deemed to be underlying causes in two patients (1.6%). Similar baseline characteristics were noted for concurrent and previous bronchodilation test cohorts, except for significant gender distribution. (Table 1)

The discriminative power of LCI, RV/TLC, and nLCI

Mean LCI and RV/TLC was 15.3 and 41.6%, with mean standard deviation of 0.83 and 1.70 for two technically acceptable measurements, respectively. Patients with either post-infectious or other etiologies had numerically higher LCI than those with idiopathic bronchiectasis; however, neither nLCI nor RV/TLC differ statistically when stratified by etiology (P>0.05, Table A in S2 Text).

LCI (AUC: 0.73, 95%CI: 0.64, 0.82) demonstrated significantly greater diagnostic power (P = 0.038) than RV/TLC (AUC: 0.62, 95%CI: 0.52, 0.72) in discriminating moderate-to-severe from mild bronchiectasis (Fig 2-a and 2-b, Table B in S2 Text), whereas both parameters had
Table 1. Clinical characteristics of bronchiectasis patients.

| Parameter                          | All bronchiectasis patients (n = 127) | Concurrent bronchodilation test cohort (n = 41)a | Historic bronchodilation test cohort (n = 47)b | P value * |
|------------------------------------|---------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------|
| **Anthropometry**                  |                                       |                                               |                                               |           |
| Age (years)                        | 44.4±14.1                             | 44.2±16.0                                     | 42.3±14.0                                     | 0.56      |
| Females (No., %)                   | 75 (59.1%)                            | 16 (39.0%)                                    | 30 (63.8%)                                    | 0.02      |
| BMI (kg/m²)                        | 20.0 (18.1–23.2)                      | 21.0±3.6                                      | 19.8±3.3                                      | 0.10      |
| Never-smokers (No., %)             | 109 (85.8%)                           | 31 (75.6%)                                    | 47 (100.0%)                                   | <0.01     |
| **History**                        |                                       |                                               |                                               |           |
| No. of exacerbations within 2 years | 3.0 (2.0–5.0)                         | 3.0 (2.0–5.0)                                 | 3.0 (2.0–5.8)                                 | 0.87      |
| **HRCT findings**                  |                                       |                                               |                                               |           |
| No. of bronchiectatic lobes        | 4.0 (3.0–6.0)                         | 5.0 (3.0–6.0)                                 | 5.0 (3.0–6.0)                                 | 0.56      |
| HRCT total score                   | 8.0 (5.0–11.0)                        | 9.5±3.9                                       | 9.2±4.0                                       | 0.69      |
| **Disease severity**               |                                       |                                               |                                               |           |
| *Bronchiectasis Severity Index*    | 6.0 (4.0–10.0)                        | 7.2±3.5                                       | 7.4±3.5                                       | 0.81      |
| **Sputum bacteriology**            |                                       |                                               |                                               |           |
| *Pseudomonas aeruginosa (No., %)   | 42 (33.1%)                            | 17 (41.5%)                                    | 18 (38.3%)                                    | 0.76      |
| Other pathogenic bacteria (No., %) | 40 (31.5%)                            | 12 (29.3%)                                    | 17 (36.2%)                                    | 0.49      |
| Commensals (No., %)                | 45 (35.4%)                            | 11 (26.8%)                                    | 12 (25.5%)                                    | 0.89      |
| **Medications within 6 months d**  |                                       |                                               |                                               |           |
| Inhaled corticosteroids (No., %)   | 33 (26.0%)                            | 13 (31.7%)                                    | 13 (27.7%)                                    | 0.68      |
| Mucolytics (No., %)                | 89 (70.1%)                            | 25 (61.0%)                                    | 38 (80.9%)                                    | 0.04      |
| Macrolides (No., %)                | 47 (37.0%)                            | 17 (41.5%)                                    | 22 (46.8%)                                    | 0.61      |
| **Underlying causes**              |                                       |                                               |                                               |           |
| Post-infectious (No., %)           | 39 (30.7%)                            | 11 (26.8%)                                    | 15 (31.9%)                                    | 0.60      |
| Miscellaneous known findings (No., %) | 34 (26.8%)                            | 10 (24.4%)                                    | 17 (36.2%)                                    | 0.23      |
| Idiopathic (No., %)                | 56 (44.1%)                            | 21 (51.2%)                                    | 17 (36.2%)                                    | 0.16      |
| **Lung function parameters**       |                                       |                                               |                                               |           |
| LCI                                | 14.6±12.0                             | 16.2 (13.7–18.2)                              | 16.4±4.0                                      | 0.94      |
| RV/TLC                             | 41.6±8.9                              | 42.3±9.2                                      | 43.2±8.6                                      | 0.05      |

Numerical data were presented as either mean ± standard deviation (SD) or median (interquartile range, IQR) as appropriate. No patient was regularly using inhaled, oral or systemic antibiotics. LCI: lung clearance index; RV/TLC: the ratio of residual volume to total lung capacity

a This cohort referred to the bronchiectasis patients who had undergone bronchodilation tests within the same day of multiple-breath nitrogen washout test and spirometry (also selected from the whole bronchiectasis cohort).
b This cohort referred to the bronchiectasis patients who had undergone bronchodilation tests within the previous 2 years (also selected from the whole bronchiectasis cohort).
c Other pathogenic bacteria for all bronchiectasis patients included *Haemophilus parainfluenzae* (n = 8, 7.3%), *Escherichia coli* (n = 5, 4.5%), *Klebsiella pneumoniae* (n = 4, 3.6%), *Serratia marcescens* (n = 2, 1.8%), *Streptococcus pneumoniae* (n = 1, 0.9%), *Moraxella catarrhalis* (n = 1, 0.9%), *Achromobacter xylosoxidans* (n = 1, 0.9%), *Proteus mirabilis* (n = 1, 0.9%), *Haemophilus haemolyticus* (n = 1, 0.9%) and *Bordetella bronchiseptica* (n = 1, 0.9%).
d Most patients had ever used more than one category of medications within the last 6 months.
e Dual underlying causes were determined in a minority of patients, thus the cumulative percentage was greater than 100%. Miscellaneous causes consisted of immunodeficiency, allergic bronchopulmonary aspergillosis, gastroesophageal reflux disease, asthma, diffuse panbronchiolitis, Kartagener syndrome, non-tuberculous mycobacteria disease, Young's syndrome, rheumatoid arthritis, lung sequestration syndrome, and lung malformation.

* P values denoted the comparison between concurrent and historic bronchodilation test cohorts.

[https://doi.org/10.1371/journal.pone.0183779.t001](https://doi.org/10.1371/journal.pone.0183779.t001)
comparable power in discriminating mild-to-moderate from severe bronchiectasis (AUC: 0.70 vs. 0.69, P = 0.839). The nLCI, however, did not confer additional discriminative performance compared with RV/TLC alone (P = 0.894) and was inferior to LCI (P = 0.020) in discriminating moderate-to-severe from mild bronchiectasis. Moreover, the nLCI had comparable discriminative performance with RV/TLC alone (P = 0.894) and was inferior to LCI (P = 0.020) in discriminating mild-to-moderate from severe bronchiectasis (Fig 2, Table B in S2 Text).

Moreover, LCI (AUC: 0.81, 95%CI: 0.73, 0.90) performed slightly better than RV/TLC (AUC: 0.72, 95%CI: 0.62, 0.82) in discriminating bronchiectasis patients with FEV₁ >80% predicted (P = 0.129). Again, adopting the nLCI did not contribute to improved discriminative performance compared with LCI (P = 0.261 for nLCI vs. RV/TLC). (Table C in S2 Text)

Consistency of LCI, RV/TLC and nLCI in reflecting clinical characteristics of bronchiectasis

Higher LCI was consistent with the clinical characteristics of bronchiectasis (all P<0.05) than RV/TLC in reflecting 3 or more bronchiectatic lobes ($\chi^2$: 31.69 vs. 14.38), HRCT total score of greater than 9 ($\chi^2$: 30.27 vs. 10.57), BSI of greater than 5 ($\chi^2$: 15.00 vs. 4.32), cystic bronchiectasis ($\chi^2$: 8.98 vs. 6.84), mosaicism ($\chi^2$: 15.01 vs. 9.29) and FEV₁ ≤80% predicted ($\chi^2$: 21.17 vs. 11.47). However, normalization of LCI (nLCI) led to decreased consistency in reflecting 3 or more bronchiectatic lobes ($\chi^2$: 11.72, P<0.001), cystic bronchiectasis ($\chi^2$: 0.01, P = 0.952), mosaicism ($\chi^2$: 3.27, P = 0.071) and FEV₁ predicted being not greater than 80% ($\chi^2$: 1.86,
P = 0.173), except for HRCT total score being greater than 9 (χ²: 10.57, P = 0.001) and BSI being greater than 5 (χ²: 5.94, P = 0.015). (Table 2)

Correlation between clinical parameters and LCI, RV/TLC, and nLCI

Both LCI and RV/TLC increased progressively with greater BSI, with highest levels of LCI and RV/TLC in severe bronchiectasis. The BSI correlated significantly with LCI (r = 0.45, P < 0.001) and RV/TLC (r = 0.36, P < 0.001), but not the nLCI (r = 0.17, P = 0.053, Fig 3). In adjusted partial correlation model, LCI positively correlated with RV/TLC (r = 0.42, P < 0.01). This applied in mild (r = 0.49, P < 0.01) and severe bronchiectasis (r = 0.45, P < 0.01), but not moderate bronchiectasis (r = 0.25, P = 0.12). (Table D in S2 Text) LCI was significantly higher in patients with RV/TLC >40% than those with RV/TLC ≤40% (S1 Fig). Moreover, in adjusted partial correlation model, FEV₁/FVC% correlated with LCI (r = -0.48, P < 0.01 in mild bronchiectasis; r = -0.62, P < 0.01 in moderate bronchiectasis; r = -0.62, P < 0.01 in severe bronchiectasis) and RV/TLC (r = -0.45, P < 0.01 in mild bronchiectasis; r = -0.36, P = 0.02 in moderate bronchiectasis; r = -0.44, P < 0.01 in severe bronchiectasis), but not nLCI (r = -0.20, P = 0.23 in mild bronchiectasis; r = -0.30, P = 0.06 in moderate bronchiectasis; r = -0.08, P = 0.64 in severe bronchiectasis; Table E in S2 Text). Nevertheless, we did not find significant correlation between functional residual capacity and RV/TLC (r = 0.09, P = 0.30).

Both LCI and RV/TLC significantly were associated with HRCT score, age, FEV₁% predicted, and cystic bronchiectasis (all P < 0.001). LCI was associated with *Pseudomonas aeruginosa* colonization, and had a borderline association with mosaicism; whereas RV/TLC correlated with gender. The nLCI had slightly greater effect sizes than LCI and RV/TLC in terms of correlation with HRCT score (estimate: 0.67, 95%CI: 0.57, 0.77), *Pseudomonas aeruginosa* colonization (estimate: -1.65, 95%CI: -2.09, -1.21), and cystic bronchiectasis (estimate: 3.28, 95%CI: 2.81, 3.74). (Table 3) Furthermore, subgroup analyses according to bronchiectasis severity showed similar variable attributes’ impacts on LCI, RV/TLC and nLCI (Tables F-H in S2 Text).
Clinical characteristics of bronchiectasis when stratified by LCI and RV/TLC

Table 4 shows the clinical characteristics (including bronchodilator response) among patients with higher or lower LCI and RV/TLC. Despite non-significant difference in symptom duration and prior exacerbation frequency, patients with higher LCI (LCI\textsuperscript{High} RV/TLC\textsuperscript{Low} and LCI\textsuperscript{High} RV/TLC\textsuperscript{High}) had more bronchiectatic lobes, and higher HRCT score and BSI, and tended to have bilateral and cystic bronchiectasis, mosaicism, colonization by potentially pathogenic microorganisms (particularly *Pseudomonas aeruginosa*), and lower FEV\textsubscript{1}\% compared with patients who had lower LCI (LCI\textsuperscript{Low} RV/TLC\textsuperscript{Low} and LCI\textsuperscript{Low} RV/TLC\textsuperscript{High}). Despite non-significantly greater post-bronchodilator FEV\textsubscript{1} in patients with LCI\textsuperscript{High} RV/TLC\textsuperscript{High}, differences in bronchodilator responses expressed either as absolute value or percentage change from baseline, were unremarkable among the four subgroups in both concurrent bronchodilation test cohort and the pooled cohort (S2 Fig). Furthermore, compared with patients in LCI\textsuperscript{High} RV/TLC\textsuperscript{Low} subgroup, those with LCI\textsuperscript{Low} RV/TLC\textsuperscript{High} were older and less likely to harbor *Pseudomonas aeruginosa*, and had greater FEV\textsubscript{1}. However, only numerically greater bronchodilator responses were demonstrated in patients with LCI\textsuperscript{Low} RV/TLC\textsuperscript{High}.

Discussion

Main findings

MBW are simple and feasible for measuring ventilation heterogeneity and the functional residual volume. Despite growing application of LCI for bronchiectasis assessment, no study has mentioned the potential impacts of RV/TLC on analysis of LCI. Conventionally, raw LCI values have been consistently reported. This study comprehensively compared the discriminative performance of LCI and RV/TLC in bronchiectasis across the whole severity spectrum, and compared with the normalized parameter (nLCI). Furthermore, we compared bronchodilator responses by stratifying the LCI and RV/TLC. Overall, our findings justify the report of raw, but not normalized, values of LCI.

Interpretation

Historically, head-to-head comparisons of LCI and RV/TLC are lacking. The positive correlations between them might be primarily attributable to more aberrant airway architectures.
associated with greater disease severity. Findings from CF showed that LCI abnormality (84%) was more common than lung hyperinflation (58%) measured with residual volume in young children [18], and that LCI was more sensitive than functional residual capacity to discriminate Pseudomonas aeruginosa plus other pathogenic bacteria infection in children [19]. However, in the study by Gustafsson et al [20], LCI had greater sensitivity to detect abnormal lung structure which incorporated air trapping >30% and bronchiectasis in CF. Our study was the first to document that LCI conferred superior discriminative performance to RV/TLC for bronchiectasis assessment. Theoretically, gas trapping leading to hyperinflation is the consequence of increased bronchial wall thickness and decreased attenuation [21] which are associated with airway remodeling following recurrent infection and inflammation; whereas LCI correlated with airway mucus plugging (which had no significant impacts on airway obstruction) [21] and bronchial wall thickness [22]. Discordant changes in lung volume and LCI have been shown in bronchiectasis following chest physiotherapy which sought to mitigate mucus plugging [23]. Therefore, LCI might have greater discriminative performance and better correlation with clinical variables of bronchiectasis than hyperinflation indices such as RV/TLC.

Normalization of LCI with RV/TLC did not contribute to improved discriminative performance or correlation with the clinical variables of bronchiectasis compared with either parameter alone. This indicated that the magnitude of hyperinflation did not significantly affect ventilation heterogeneity. In the study by Haidopoulou et al., adjustment of LCI with airway and/or equipment dead space did not improve the sensitivity in identifying early CF lung disease (which frequently included bronchiectasis) in children [24]. Thus, LCI was virtually

Table 3. Fixed-effect estimates in multivariate linear mixed model of the clinical variable attributes' impacts on lung clearance index, the ratio of residual volume to total lung capacity, and normalized lung clearance index.

|                      | LCI                  | RV/TLC               | nLCI                  |
|----------------------|----------------------|----------------------|-----------------------|
|                      | Estimate             | P value              | 95% CI                | Estimate             | P value              | 95% CI                | Estimate             | P value              | 95% CI                |
| Intercept            | 16.21                | <0.001               | 14.98, 17.44          | 37.54                | <0.001               | 36.31, 38.77          | 43.04                | <0.001               | 41.81, 44.27          |
| No. of bronchiectatic lobes | -0.05                | 0.626               | -0.66, 0.55          | 0.02                | 0.846               | -0.19, 0.23          | 0.01                | 0.968               | -0.21, 0.22          |
| HRCT total score *   | 0.39                 | <0.001              | 0.30, 0.49          | 0.31                | <0.001              | 0.28, 0.30          | 0.67                | <0.001              | 0.57, 0.77          |
| Age                  | 0.04                 | <0.001              | 0.03, 0.05          | 0.29                | <0.001              | 0.28, 0.30          | -0.18               | <0.001              | -0.20, -0.17         |
| FEV1 predicted%      | 0.09                 | <0.001              | -0.10, -0.74         | 0.19                | <0.001              | 0.20, -0.18          | 0.03                | <0.001              | -0.04, -0.02         |
| Sex                  | -                    | -                   | -                   | -                   | -                   | -                   | -                   | -                   | -                   |
| Males                | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            |
| Females              | 0.14                 | 0.475               | -0.24, 0.51          | 1.54                | <0.001              | 1.17, 1.91          | -0.86               | <0.001              | -1.23, -0.49         |
| Pseudomonas aeruginosa colonization | -                    | -                   | -                   | -                   | -                   | -                   | -                   | -                   | -                   |
| Yes                  | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            |
| No                   | -0.85                | <0.001              | -1.29, -0.41         | 0.17                | 0.441               | -0.27, 0.61          | -1.65               | <0.001              | -2.09, -1.21         |
| Cystic bronchiectasis ** | -                    | -                   | -                   | -                   | -                   | -                   | -                   | -                   | -                   |
| Yes                  | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            |
| No                   | 1.11                 | <0.001              | 0.64, 1.57          | -1.35               | <0.001              | -1.82, -0.89         | 3.28                | <0.001              | 2.81, 3.74          |
| Mosaicism            | -                    | -                   | -                   | -                   | -                   | -                   | -                   | -                   | -                   |
| Yes                  | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            | Reference            |
| No                   | -0.47                | 0.051               | -0.95, 0.01         | -0.91               | <0.001              | -1.38, -0.44         | -0.65               | <0.007              | -1.12, -0.17         |

95%CI: 95% confidence interval. LCI: lung clearance index; RV/TLC: the ratio of residual volume to total lung capacity; nLCI: normalized lung clearance index. Data in bold indicated the statistical analyses with significance.

* Modified Reiff score

** Denoted the presence of cystic changes of the dilated bronchi on chest HRCT.

https://doi.org/10.1371/journal.pone.0183779.t003
Table 4. Clinical characteristics of bronchiectasis patients stratified by LCI and RV/TLC levels.

| Parameter                  | LCI\(^{\text{Low}}\)/RV/TLC\(^{\text{Low}}\) (n = 45) | LCI\(^{\text{Low}}\)/RV/TLC\(^{\text{High}}\) (n = 19) | LCI\(^{\text{High}}\)/RV/TLC\(^{\text{Low}}\) (n = 19) | LCI\(^{\text{High}}\)/RV/TLC\(^{\text{High}}\) (n = 44) | P     |
|----------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-------|
| **Anthropometry**          |                                                    |                                                    |                                                    |                                                    |       |
| Age (years)                | 41.6±13.2                                          | 52.9±13.1                                          | 36.5±12.2                                          | 48.0 (22.3)                                         | <0.001|
| Females (No., %)           | 30 (66.7%)                                         | 10 (52.6%)                                         | 9 (47.4%)                                          | 25 (56.8%)                                         | 0.472 |
| BMI (kg/m\(^{2}\))        | 20.9±3.3                                           | 20.9±3.8                                           | 20.0±2.8                                           | 20.3±3.7                                           | 0.716 |
| **History**                |                                                    |                                                    |                                                    |                                                    |       |
| Duration of symptoms (yrs) | 10.0 (16.0)                                        | 18.9±14.3                                          | 15.0 (9.0)                                         | 15.0 (18.3)                                         | 0.091 |
| No. of exacerbations within the previous year | 1.0 (2.0)                                          | 1.0 (1.0)                                          | 1.7±1.3                                            | 2.0 (2.0)                                          | 0.262 |
| **HRCT findings**          |                                                    |                                                    |                                                    |                                                    |       |
| No. of bronchiectatic lobes| 3.0 (2.0)                                          | 4.0 (3.0)                                          | 5.0 (2.0)                                          | 5.0 (2.0)                                          | <0.001|
| HRCT total score           | 5.0 (4.5)                                          | 7.7±3.9                                            | 10.2±3.6                                          | 10.5±3.6                                          | <0.001|
| Predominantly middle/lower lobe bronchiectasis | 32 (71.1%)                                         | 10 (52.6%)                                         | 15 (78.9%)                                         | 28 (63.6%)                                         | 0.312 |
| Bilateral bronchiectasis   | 29 (64.4%)                                         | 15 (78.9%)                                         | 19 (100.0%)                                        | 43 (97.7%)                                         | <0.001|
| Cystic bronchiectasis *    | 23 (51.1%)                                         | 13 (68.4%)                                         | 14 (73.7%)                                         | 37 (84.1%)                                         | 0.009 |
| Mosaicism                  | 25 (55.6%)                                         | 14 (73.7%)                                         | 16 (84.2%)                                         | 41 (93.2%)                                         | <0.001|
| **Disease severity**       |                                                    |                                                    |                                                    |                                                    |       |
| Bronchiectasis Severity Index | 4.8±3.6                                           | 5.0 (6.0)                                          | 6.5±2.8                                            | 9.0 (6.0)                                          | <0.001|
| **Sputum bacterial colonization** |                                                    |                                                    |                                                    |                                                    |       |
| Pseudomonas aeruginosa (No., %) | 7 (15.6%)                                         | 3 (15.8%)                                         | 6 (31.6%)                                          | 15 (34.1%)                                         | 0.026 |
| Other pathogenic bacteria (No., %) | 6 (13.3%)                                         | 1 (5.3%)                                           | 6 (31.6%)                                          | 19 (43.2%)                                         | <0.001|
| **Lung function**          |                                                    |                                                    |                                                    |                                                    |       |
| FEV\(_{1}\) % predicted    | 81.0±19.5                                          | 68.6±18.6                                          | 57.9±16.3                                          | 47.7±19.2                                          | <0.001|
| Post-bronchodilator FEV\(_{1}\) change (L) \(^{b}\) | 0.15±0.21                                          | 0.12±0.09                                          | 0.05±0.14                                          | 0.16±0.13                                          | 0.362 |
| Post-bronchodilator FEV\(_{1}\) change (%) \(^{b}\) | 7.9±14.4                                           | 7.0±5.2                                            | 3.4±8.1                                            | 12.1±8.5                                           | 0.171 |
| Post-bronchodilator FEV\(_{1}\) change (L) \(^{c}\) | 0.13±0.19                                          | 0.13±0.11                                          | 0.11±0.14                                          | 0.14±0.11                                          | 0.883 |
| Post-bronchodilator FEV\(_{1}\) change (%) \(^{c}\) | 8.1±15.1                                           | 6.5 (8.8)                                          | 8.1±10.6                                          | 11.5±8.8                                           | 0.163 |

For LCI, “Low” denoted the values being equal to or lower than the median (14.6), whereas “high” indicated the values being higher than the median (14.6). For RV/TLC%, “Low” denoted the values being equal to or lower than the median (41.5%), whereas “high” indicated the values being higher than the median (41.5%). Significant bronchodilator response was defined as post-bronchodilator FEV\(_{1}\) increased by at least 12% and 200 ml. The P value demonstrated inside the table referred to the comparison among the four groups.

* Denoted the presence of cystic changes of the dilated bronchi on chest HRCT.

\(^{a}\) Other colonized bacteria in this study included Haemophilus parainfluenzae, Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Streptococcus pneumoniae, Moraxella catarrhalis, Achromobacter xylosoxidans, Proteus mirabilis, Haemophilus haemolyticus and Bordetella bronchiseptica.

\(^{b}\) Statistical analyses were done in 7, 8, 7 and 19 patients with available data (bronchodilator tests performed within the same day of the multiple-breath washout test) in groups LCI\(^{\text{Low}}\)/RV/TLC\(^{\text{Low}}\), LCI\(^{\text{Low}}\)/RV/TLC\(^{\text{High}}\), LCI\(^{\text{High}}\)/RV/TLC\(^{\text{Low}}\), and LCI\(^{\text{High}}\)/RV/TLC\(^{\text{High}}\), respectively (Concurrent bronchial dilation test cohort).

\(^{c}\) Statistical analyses were done in 19, 13, 16 and 40 patients with available data in groups LCI\(^{\text{Low}}\)/RV/TLC\(^{\text{Low}}\), LCI\(^{\text{Low}}\)/RV/TLC\(^{\text{High}}\), LCI\(^{\text{High}}\)/RV/TLC\(^{\text{Low}}\), and LCI\(^{\text{High}}\)/RV/TLC\(^{\text{High}}\), respectively. Results for patients who performed bronchiectasis test at baseline visits and those who had performed within the previous 2 years were pooled for analysis (Concurrent & historic bronchial dilation test cohort).

https://doi.org/10.1371/journal.pone.0183779.t004

unaffected by dead space volume, either from the respiratory tract or testing equipment. One might argue the numerically greater correlation of nLCI with clinical parameters; however, the priority of clinical relevance should be given to discriminative performance and concordance with other clinical variables. Our findings remained unchanged following stratification of
bronchiectasis severity, suggesting that disease severity might not be a modifier of the relationship between LCI and RV/TLC. Therefore, the additive value of normalization with RV/TLC is minimal.

Because of airway remodeling and mucus plugging, ventilation heterogeneity and hyperinflation might be reduced following bronchodilation. Unexpectedly, stratifying the LCI and RV/TLC did not reveal different bronchodilator responses. Recent literature suggested that RV more sensitively reflected airway reversibility than spirometric parameters (including FEV₁) in obstructive lung disease [25], and that hyperinflation was associated with greater bronchodilator responses in patients with chronic obstructive pulmonary disease who had poorer lung function [26]. These collectively indicated the potential significance of hyperinflation indices (including RV/TLC) as markers of bronchodilator responses. Contrarily, documentation of different bronchodilator responses when stratified by LCI has not been available. In our study, patients with consistently higher LCI and RV/TLC showed greater disease severity and numerically greater bronchodilator responses, which might have approached statistical significance if sample sizes were further increased. Nevertheless, when specifically focusing on LCI\textsuperscript{High}RV/TLC\textsuperscript{Low} and LCI\textsuperscript{Low}RV/TLC\textsuperscript{High} subgroup, only numerically greater bronchodilator responses were shown in the latter subgroup. However, when analyzing previous records (within 2 years), this trend was slightly tempered. Due to limited sample sizes, we cannot justify the additive value of RV/TLC to LCI in identifying different bronchodilator responses.

Limitations

Our findings are limited by the sample sizes (particularly bronchodilator response) from single research center. No longitudinal follow-up was scheduled to determine temporal stability of LCI or RV/TLC. We did not stratify the levels of LCI based on the previously published “normal values” or the cut-off values derived from receiver operation characteristic curve because all patients in this study demonstrated increased LCI and no healthy subject was enrolled. In light of the “gold standard” for classification, we think that the stratification based on the median levels among all bronchiectasis patients remained to be the alternative approach for classification. The use of MBW for the measurement of LCI might have limited value particularly among patients with severe airflow obstruction or emphysema, in whom the true value of functional residual volume might have been underestimated by the washout methods. Specifically, MBW does not take into account the trapped gas or completely obstructed lung zones. In this study, there lacks a validation of the functional residual capacity using the same pulmonary function testing instrument for LCI measurement. It should be recognized that body plethysmography remains the gold standard for measuring RV/TLC. However, for ease of patient’s cooperation, body plethysmography was not additionally performed. The MBW method used in our study has limitations (not validated in this population). There was an absence of age-matched normative data at our local site. We only utilized simple normalization algorithms for adjusting LCI, based on the priori assumption that ventilation heterogeneity could be affected by the magnitude of hyperinflation. Nevertheless, such an attempt remains flawed because nLCI could be simultaneously influenced by different levels of LCI and RV/TLC, for instance, lower nLCI could be derived from lower LCI plus higher RV/TLC which might be contradictory to our research hypothesis. We cannot fully exclude other more sensitive parameters aside from LCI. However, findings from Haidopoulou et al. have minimized the possibility of deriving more sensitive indices [24]. Additionally, there still might be a bias in the influence of bronchodilation response because it was not assessed in all those with FEV₁ >80%. Finally, the criterion for defining exacerbations was not based on the latest expert consensus, which might have affected some of the data interpretation.
Clinical implications

LCI is a sensitive marker for assessment of bronchiectasis [3], primary ciliary dyskinesia [27] and CF [20]. From physiological points of view, potential confounding of LCI by RV/TLC cannot be thoroughly excluded. Importantly, our comprehensive analysis has justified the reporting of raw values of LCI against further attempts to normalize with RV/TLC in bronchiectasis. For clinicians, LCI can be reported without further needs to incorporate the levels of RV/TLC. In other words, RV/TLC confers no significant additional benefits for ventilation heterogeneity measurement with LCI. Caution should be exercised when predicting bronchodilator responses with LCI in combination of RV/TLC.

Supporting information

S1 File. RV TLC LCI.xls. This is an elementary electronic data base with information pertinent to the clinical information and lung function assessment in patients with bronchiectasis. (XLS)

S1 Text. STROBE checklist. (DOC)

S2 Text. (DOC)

S1 Fig. Comparison of LCI in patients with or without RV/TLC >0.40. (TIF)

S2 Fig. Difference between pre- and post-bronchodilator FEV₁ in patients with bronchiectasis. (A). Difference between pre- and post-bronchodilator FEV₁ (expressed in absolute values) in bronchiectasis patients who underwent bronchodilation test within the same day of multiple-breath nitrogen washout test and spirometry; Statistical analyses were done in 7, 8, 7 and 19 patients with available data (bronchodilator tests performed within the same day of the multiple-breath washout test) in groups LCI_{Low}RV/TLC_{Low}, LCI_{Low}RV/TLC_{High}, LCI_{High}RV/TLC_{Low}, and LCI_{High}RV/TLC_{High}, respectively. Overall, no significant difference was observed when comparing the data among the four subgroups. (B). Difference between pre- and post-bronchodilator FEV₁ (expressed in percentage) in bronchiectasis patients who underwent bronchodilation test within the same day of multiple-breath nitrogen washout test and spirometry; Statistical analyses were done in 7, 8, 7 and 19 patients with available data (bronchodilator tests performed within the same day of the multiple-breath washout test) in groups LCI_{Low}RV/TLC_{Low}, LCI_{Low}RV/TLC_{High}, LCI_{High}RV/TLC_{Low}, and LCI_{High}RV/TLC_{High}, respectively. Overall, no significant difference was observed when comparing the data among the four subgroups. (C). Difference between pre- and post-bronchodilator FEV₁ (expressed in absolute values) in all bronchiectasis patients who had ever undergone bronchodilation test (either at the baseline visit or within the previous 2 years); Statistical analyses were done in 19, 13, 16 and 40 patients with available data (bronchodilator tests performed within the same day of the multiple-breath washout test) in groups LCI_{Low}RV/TLC_{Low}, LCI_{Low}RV/TLC_{High}, LCI_{High}RV/TLC_{Low}, and LCI_{High}RV/TLC_{High}, respectively. Overall, no significant difference was observed when comparing the data among the four subgroups. (D). Difference between pre- and post-bronchodilator FEV₁ (expressed in percentage) in all bronchiectasis patients who had ever undergone bronchodilation test (either at the baseline visit or within the previous 2 years); Statistical analyses were done in 19, 13, 16 and 40 patients with available data (bronchodilator tests performed within the same day of the multiple-breath washout test) in groups LCI_{Low}RV/TLC_{Low}, LCI_{Low}RV/TLC_{High}, LCI_{High}RV/TLC_{Low}, and LCI_{High}RV/TLC_{High}, respectively.
Overall, no significant difference was observed when comparing the data among the four sub-groups.

(TIF)

Author Contributions

**Conceptualization:** Wei-jie Guan, Rong-chang Chen, Nan-shan Zhong.

**Data curation:** Wei-jie Guan, Jing-jing Yuan, Yan Huang.

**Formal analysis:** Wei-jie Guan.

**Funding acquisition:** Wei-jie Guan, Rong-chang Chen, Nan-shan Zhong.

**Investigation:** Wei-jie Guan, Jing-jing Yuan, Yan Huang, Hui-min Li.

**Methodology:** Wei-jie Guan, Jing-jing Yuan, Yan Huang, Hui-min Li.

**Project administration:** Wei-jie Guan.

**Resources:** Hui-min Li, Nan-shan Zhong.

**Supervision:** Wei-jie Guan, Rong-chang Chen, Nan-shan Zhong.

**Validation:** Wei-jie Guan.

**Visualization:** Wei-jie Guan.

**Writing – original draft:** Wei-jie Guan.

**Writing – review & editing:** Wei-jie Guan, Jing-jing Yuan, Yan Huang, Hui-min Li, Rong-chang Chen, Nan-shan Zhong.

References

1. Verbanck S, Paiva M, Schuermans D, Hanon S, Vincken W, Van Muylem A. Relationships between the lung clearance index and conductive and acinar ventilation heterogeneity. *Am J Physiol (1985)*. 2012; 112:782–90

2. O’Neil K, Tunney MM, Johnston E, Rowan S, Downey DG, Rendall J, et al. Lung clearance index in adults and children with cystic fibrosis. *Chest* 2016; 150: 1323–32 https://doi.org/10.1016/j.chest.2016.06.029 PMID: 27395423

3. Rowan RA, Bradley JM, Bradbury I, Lawson J, Lynch T, Gustafsson P, et al. Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. *Am J Respir Crit Care Med* 2014; 189: 886–92 https://doi.org/10.1164/rccm.201310-1747OC PMID: 24428575

4. Gonem S, Scadding A, Soares M, Singapuri A, Gustafsson P, Otul C, et al. Lung clearance index in adults with non-cystic fibrosis bronchiectasis. *Respir Res* 2014; 15: 59 https://doi.org/10.1186/1465-9921-15-59 PMID: 24884343

5. Guan WJ, Gao YH, Xu G, Lin ZY, Tang Y, Li HM, et al. Characterization of lung function impairment in adults with bronchiectasis. *Plos One* 2014; 9, e113373 https://doi.org/10.1371/journal.pone.0113373 PMID: 25405614

6. Guan WJ, Yuan JJ, Gao YH, Li HM, Zheng JP, Chen RC, Zhong NS. Maximal mid-expiratory flow is a surrogate marker of lung clearance index for assessment of adults with bronchiectasis. *Sci Rep* 2016; 6: 28467 https://doi.org/10.1038/srep28467 PMID: 27339787

7. Angrill J, Agusti C, De Celis R, Filella X, Rañó A, Elena M, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. *Am J Respir Crit Care Med* 2001; 164: 1628–32 https://doi.org/10.1164/ajrccm.164.9.2105083 PMID: 11719301

8. Zheng L, Lam WK, Tipoe GL, Shum IH, Yan C, Leung R, Sun J, Ooi GC, Tsang KW. Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways *in vivo*. *Eur Respir J* 2002; 20: 170–6 PMID: 12165666

9. Davi D, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of *Pseudomonas aeruginosa* on pulmonary function in patients with bronchiectasis. *Eur Respir J* 2006; 28:974–9 https://doi.org/10.1183/09031936.06.00074605 PMID: 16899482
10. Horsley AR, Gustafsson PM, Macleod KA, Saunders C, Greening AP, Porteous DJ, et al. Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. *Thorax*. 2008; 63: 135–40 https://doi.org/10.1136/thx.2007.082628 PMID: 17675315

11. Rossi A, Aisanov Z, Avdeev S, Di Maria G, Donner CF, Izquierdo JL, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. *Respir Med*. 2015; 109: 785–802 https://doi.org/10.1016/j.rmed.2015.03.010 PMID: 25892293

12. Zhang W, Lu H, Peng L, Ren X, Lu Y, An L, et al. Chronic bronchitis leads to accelerated hyperinflation in COPD patients during exercise. *Respirology*. 2015; 20: 618–25 https://doi.org/10.1111/resp.12504 PMID: 25799924

13. Martínez-García MA, Perpiñá-Tordera M, Soler-Cataluña JJ, Román-Sánchez P, Lloris-Bayo A, González-Molina A. Dissociation of lung function, dyspnea ratings and pulmonary extension in bronchiectasis. *Respir Med*. 2007; 101: 2248–53 https://doi.org/10.1016/j.rmed.2007.06.028 PMID: 17698334

14. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. *Am J Radiol*. 1995; 165: 261–267

15. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, et al. ERS/ATS consensus statement: Consensus statement for inert gas washout measurement using multiple- and single-breath tests. *Eur Respir J*. 2013; 41: 507–222 https://doi.org/10.1183/09031936.00069712 PMID: 23397305

16. Zheng JP, Zhong NS. Normative values of pulmonary function testing in Chinese adults. *Chin Med J*. 2002; 115: 50–4 PMID: 11930658

17. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index: An international derivation and validation study. *Am J Respir Crit Care Med*. 2014; 189: 576–85 https://doi.org/10.1164/rccm.201309-1575OC PMID: 24328736

18. Owens CM, Aurora P, Stanojevic C, Bush A, Wade A, Oliver C, et al; London Cystic Fibrosis Collaboration. Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF. *Thorax*. 2011; 66: 481–8 https://doi.org/10.1136/thx.2010.150375 PMID: 21422040

19. Kraemer R, Baldwin DJ, Ammann RA, Frey U, Gallati S. Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis. *Respir Res*. 2006; 30: 138

20. Gustafsson PM, De Jong PA, Tiddens HA, Linblad A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. *Thorax*. 2008; 63: 129–34 https://doi.org/10.1136/thx.2007.077784 PMID: 17675316

21. Roberts HR, Wells AU, Milne DG, Rubens MB, Kolbe J, Cole PJ, Hansell DM. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. *Thorax*. 2000; 55: 198–204 https://doi.org/10.1136/thorax.55.3.198 PMID: 10679538

22. Stahl M, Wielputz MO, Graeber SY, Joachim C, Sommerburg O, Kauczor HU, et al. Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children With Cystic Fibrosis. *Am J Respir Crit Care Med*. 2017; 195: 349–59 https://doi.org/10.1164/rccm.201604-0893OC PMID: 27575911

23. Grillo L, Irving S, Hansell DM, Nair A, Annan B, Ward S, et al. The reproducibility and responsiveness of the lung clearance index in bronchiectasis. *Eur Respir J*. 2015; 46: 1645–53 https://doi.org/10.1183/13993003.00152-2015 PMID: 26341989

24. Haidopoulos K, Lum S, Turcu S, Guinard C, Aurora P, Stocks J, Sonnappa S. Alveolar LCI vs. standard LCI in detecting early CF lung disease. *Respir Physiol Neurobiol*. 2012; 180: 247–51 https://doi.org/10.1016/j.resp.2011.11.016 PMID: 22172773

25. McCartney CT, Weis MN, Ruppel GL, Nayak RP. Residual Volume and Total Lung Capacity to Assess Reversibility in Obstructive Lung Disease. *Respir Care*. 2016; 6: 1505–12

26. Chen C, Jian W, Gao Y, Xie Y, Song Y, Zheng J. Early COPD patients with lung hyperinflation associated with poorer lung function but better bronchodilator responsiveness. *Int J Chron Obstruct Pulm Dis*. 2016; 11: 2519–26

27. Irving SJ, Ives A, Davies G, Donovan J, Edey AJ, Gill SS, et al. Lung Clearance Index and High-Resolution Computed Tomography Scores in Primary Ciliary Dyskinesia. *Am J Respir Crit Care Med*. 2013; 188: 545–9 https://doi.org/10.1164/rccm.201304-0800OC PMID: 23815669